Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Company Deals

Gilead and Lakefront Complete $1.675B Acquisition of Ouro Medicines – Securing BCMAxCD3 T Cell Engager for Autoimmune Diseases

Fineline Cube Jun 5, 2026
Company Deals

Pfizer Licenses Chai Discovery’s AI Platform for Drug Discovery – Gains Early Access to Breakthrough Chai-3 Model for Antibody Design

Fineline Cube Jun 5, 2026
Company Deals

Everest Medicines Secures Asia-Pacific Rights to Mabworks’ Obexelimab β in $30.9M Deal – First-in-Class CD20 Antibody for NMOSD

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026
Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026
Company Deals Medical Device

Siemens Healthineers Diagnostics Sale: Blackstone, CVC, KKR Explore €6 B Deal

Fineline Cube Sep 15, 2025

Siemens Healthineers AG (ETR: SHL), a Germany-based medical device giant is reportedly in exploratory talks...

Company Deals

Baheal’s 24% Take‑over of Tianjin Jikun Secures Rights to Pulmonary Fibrosis Drug JK1033

Fineline Cube Sep 15, 2025

China‑based Baheal Pharmaceutical Group (SHE: 301015) announced a strategic cooperation agreement with Tianjin Jikun Pharmaceutical...

Company Deals

BMS Sells 60% Shanghai Stake to Hillhouse Capital, Shifting Focus to Growth

Fineline Cube Sep 15, 2025

A leaked internal email from US major Bristol-Myers Squibb (BMS; NYSE: BMY) has recently surfaced...

Policy / Regulatory

NMPA Releases 96th Reference Listed Drugs Catalog, Adding 42 New Generic Specifications

Fineline Cube Sep 15, 2025

The National Medical Products Administration (NMPA) has just published the 96th edition of its Reference...

Company Drug

CSPC Pharmaceutical Group Submits Anbenitamab for NMPA Approval in HER2‑Positive Gastric Cancer

Fineline Cube Sep 12, 2025

CSPC Pharmaceutical Group (HKG: 1093) announced today that Anbenitamab Antibody Injection (KN026), co‑developed with Alphamab...

Company Drug

BioNTech and BMS Reveal Promising Interim Results for Pumitamig in ES‑SCLC

Fineline Cube Sep 12, 2025

BioNTech SE (NASDAQ: BNTX) and Bristol-Myers Squibb (BMS, NYSE: BMY) disclosed interim data from a...

Company Drug

Summit Therapeutics Presents 2025 HARMONi Study Results at World Lung Cancer Conference

Fineline Cube Sep 12, 2025

Summit Therapeutics (NASDAQ: SMMT) disclosed longer‑term progression‑free survival (PFS) data from its HARMONi trial of...

Company

Guangzhou’s Bio‑Thera Solutions Secures $5.4 Million Milestone from Intas Pharma

Fineline Cube Sep 12, 2025

Bio-Thera Solutions Ltd. (SHA: 688177) announced today that it has received a $5.4 million milestone payment...

Company Policy / Regulatory

FDA Launches Aggressive Campaign to Curb Misleading Drug Advertisements

Fineline Cube Sep 12, 2025

The U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration...

Company

MSD scrapes £1 billion UK expansion, shifts life‑science research to the US

Fineline Cube Sep 12, 2025

US‑based pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced the cancellation of...

Company Drug

FibroX Therapeutics Secures IND Approval for FibroCell in Lumbar Disc Degeneration

Fineline Cube Sep 12, 2025

Shanghai‑based FibroX Therapeutics announced that its investigational new drug (IND) application for FibroCell, an allogeneic...

Drug Policy / Regulatory

NMPA Unveils 30‑Working‑Day Pathway to Accelerate Innovative Drug Trials

Fineline Cube Sep 12, 2025

The National Medical Products Administration (NMPA) announced a new regulatory framework—Announcement No. 86 of 2025—that promises to...

Company Drug

Genrix Bio Secures NMPA Approval for GR1803 Bispecific Antibody in Systemic Lupus Erythematosus

Fineline Cube Sep 11, 2025

China‑based Genrix Biopharmaceutical Co., Ltd. (SHA: 688443) announced that the National Medical Products Administration (NMPA)...

Company Deals

GenFleet Therapeutics Surges onto Hong Kong Main Board, Raising HK$1.58 B

Fineline Cube Sep 11, 2025

China‑based GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) completed a successful initial public offering (IPO) on the...

Company Deals Drug

Remedium Bio Teams Up With Eli Lilly to Push Gene‑Therapy Frontiers for Diabetes and Obesity

Fineline Cube Sep 11, 2025

Remedium Bio, Inc. (Remedium) announced a multi‑target R&D partnership with Eli Lilly & Co. (NYSE: LLY) to...

Company Deals

YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront

Fineline Cube Sep 11, 2025

The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...

Company Drug

Novartis Secures Tabrecta Approval in China for METex14 NSCLC

Fineline Cube Sep 11, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its MET‑receptor tyrosine kinase inhibitor Tabrecta (capmatinib...

Company Drug Policy / Regulatory

China to Add HPV Vaccine to National Immunization Program, Pledges Free Shots for Eligible Girls

Fineline Cube Sep 11, 2025

At a State Council Information Office press conference, Deputy Director of the National Health Commission...

Policy / Regulatory

China’s Drug Evaluation Authority Issues Draft Rules for Class I ATMP Meetings

Fineline Cube Sep 11, 2025

The Center for Drug Evaluation (CDE), part of China’s National Medical Products Administration (NMPA), published...

Policy / Regulatory

China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach

Fineline Cube Sep 11, 2025

The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...

Posts pagination

1 … 116 117 118 … 678

Recent updates

  • Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate
  • China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development
  • Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform
  • Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
  • SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.